Choreo LLC Makes New Investment in The Cooper Companies, Inc. (NASDAQ:COO)

Choreo LLC purchased a new position in The Cooper Companies, Inc. (NASDAQ:COO) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 3,841 shares of the medical device company’s stock, valued at approximately $333,000.

Several other large investors also recently made changes to their positions in COO. Franklin Resources Inc. boosted its position in Cooper Companies by 1.2% during the fourth quarter. Franklin Resources Inc. now owns 3,401 shares of the medical device company’s stock worth $1,287,000 after purchasing an additional 41 shares during the period. LRI Investments LLC boosted its holdings in shares of Cooper Companies by 4.5% during the 2nd quarter. LRI Investments LLC now owns 2,595 shares of the medical device company’s stock worth $227,000 after buying an additional 112 shares during the period. Commonwealth Equity Services LLC grew its stake in Cooper Companies by 0.8% in the 2nd quarter. Commonwealth Equity Services LLC now owns 15,600 shares of the medical device company’s stock valued at $1,362,000 after buying an additional 118 shares during the last quarter. First Horizon Advisors Inc. raised its holdings in Cooper Companies by 4.8% in the 2nd quarter. First Horizon Advisors Inc. now owns 2,709 shares of the medical device company’s stock worth $236,000 after acquiring an additional 125 shares during the period. Finally, American International Group Inc. lifted its position in Cooper Companies by 1.0% during the 4th quarter. American International Group Inc. now owns 13,229 shares of the medical device company’s stock worth $5,006,000 after acquiring an additional 137 shares during the last quarter. Institutional investors own 24.39% of the company’s stock.

Insiders Place Their Bets

In other news, COO Daniel G. Mcbride sold 114,992 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $105.48, for a total value of $12,129,356.16. Following the sale, the chief operating officer now owns 44,696 shares in the company, valued at approximately $4,714,534.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, COO Daniel G. Mcbride sold 114,992 shares of Cooper Companies stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $105.48, for a total value of $12,129,356.16. Following the completion of the transaction, the chief operating officer now owns 44,696 shares in the company, valued at $4,714,534.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Brian G. Andrews sold 24,788 shares of the stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $105.90, for a total value of $2,625,049.20. Following the sale, the chief financial officer now owns 6,614 shares in the company, valued at $700,422.60. The disclosure for this sale can be found here. Insiders sold 141,381 shares of company stock worth $14,927,361 over the last three months. 2.00% of the stock is currently owned by corporate insiders.

Cooper Companies Price Performance

Shares of Cooper Companies stock opened at $109.83 on Wednesday. The Cooper Companies, Inc. has a twelve month low of $75.93 and a twelve month high of $112.38. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.18 and a current ratio of 1.99. The firm has a market cap of $21.87 billion, a P/E ratio of 64.61, a price-to-earnings-growth ratio of 2.60 and a beta of 0.98. The firm’s 50-day simple moving average is $96.10 and its 200-day simple moving average is $95.21.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings data on Wednesday, August 28th. The medical device company reported $0.96 earnings per share for the quarter, beating the consensus estimate of $0.91 by $0.05. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $997.30 million. Cooper Companies had a return on equity of 9.08% and a net margin of 9.45%. The company’s revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.84 EPS. As a group, research analysts expect that The Cooper Companies, Inc. will post 3.66 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on COO shares. Jefferies Financial Group upgraded Cooper Companies from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $107.00 to $115.00 in a research note on Tuesday, July 16th. Piper Sandler upped their price target on Cooper Companies from $115.00 to $120.00 and gave the stock an “overweight” rating in a report on Thursday, August 29th. Stifel Nicolaus reissued a “buy” rating and issued a $115.00 price objective (up from $110.00) on shares of Cooper Companies in a research report on Thursday, August 29th. Robert W. Baird boosted their target price on shares of Cooper Companies from $118.00 to $125.00 and gave the stock an “outperform” rating in a research report on Thursday, August 29th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Cooper Companies in a report on Thursday, August 29th. Four investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $115.00.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.